HC Wainwright Issues Positive Outlook for Cybin Earnings

Cybin Inc. (NYSE:CYBN) – Equities research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Cybin in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.51) for the quarter, up from their prior estimate of ($0.53). HC Wainwright has a “Buy” rating and a $190.00 price target on the stock. The consensus estimate for Cybin’s current full-year earnings is ($4.88) per share. HC Wainwright also issued estimates for Cybin’s Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.62) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at $3.84 EPS.

Separately, Canaccord Genuity Group dropped their price target on shares of Cybin from $96.00 to $86.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

Cybin Trading Up 0.9 %

Shares of NYSE:CYBN opened at $9.86 on Thursday. The company’s 50 day moving average is $9.78. The company has a market cap of $197.83 million, a P/E ratio of -1.48 and a beta of 0.44. Cybin has a 12-month low of $6.50 and a 12-month high of $19.85.

Hedge Funds Weigh In On Cybin

A hedge fund recently bought a new stake in Cybin stock. Sanctuary Advisors LLC purchased a new stake in shares of Cybin Inc. (NYSE:CYBN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 131,252 shares of the company’s stock, valued at approximately $36,000. Institutional investors own 17.94% of the company’s stock.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.